Gubra A/S (GUBRA)
Copenhagen Exchange · Denmark · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 289.00 |
|---|---|
| 52-week range | 272.00 – 557.50 |
| Return, 1 month / 3 months | −5.4% / −18.1% |
| Return, 1 year / 3 years | −31.8% / +244.1% |
| Trend | Below its 200-day average |
| RSI (14) | 42 |
| Volatility (1 year) | 52.2% |
| Worst drawdown (1 year) | -48.5% |
| Average daily value traded | 10.41M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Gubra A/S is a Danish biotechnology company based in Horsholm that works on peptide-based drug discovery and development. It runs its own research programmes in areas such as metabolic and gastrointestinal disease, and it also provides preclinical services to pharmaceutical and biotechnology customers, including pharmacology studies and disease models. The company combines contract research work with its internal drug pipeline, serving clients and partners in the life sciences sector.
Gubra A/S trades under the code GUBRA on the Copenhagen Exchange in Denmark, with its price quoted in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Gubra A/S (GUBRA) trades on the Copenhagen Exchange in Denmark. It last closed at DKK 289.00 on 23 October 2026.
Its price-based Market X-Ray is 25 out of 100 (a weak price profile), ranking 139 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.8% and over the last three months it fell 18.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Copenhagen Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 13 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.4% | ||
| From 52-week high | -45.9% | ||
| Momentum | 14 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -18.1% | ||
| 6-month return | -11.8% | ||
| 12-month return, skipping the last month | -27.9% | ||
| Stability (higher is calmer) | 16 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 52.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -48.5% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 10.41M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −2.1% |
|---|---|
| 1 month | −5.4% |
| 3 months | −18.1% |
| 6 months | −11.8% |
| 1 year | −31.8% |
| 3 years | +244.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 326.98 / 358.60 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 12.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Jun 2025 | DKK 61.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Copenhagen Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.